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Abstract
Background: Based on the well-recognized etiological role of human papillomavirus (HPV) in cervical, anogenital
and oropharyngeal carcinogenesis, a potential role of HPV in colorectal carcinogenesis has been suggested. For
that reason, the aim of the present study was to investigate the presence of HPV DNA in colorectal carcinomas
(CRC) and to study overexpression of p16
INK4A as a marker for the presence of an active HPV oncoprotein E7. These
findings were correlated with clinical and pathological prognostic factors of CRC.
Methods: The presence of HPV was assessed using a multiplex PCR system of 10 non-biotinylated primers. The
amplified fragments of HPV positive samples were further analyzed by a highly sensitive, broad spectrum SPF10
PCR and subsequently genotyped using reverse hybridization in a line probe assay.
P16
INK4A protein expression was investigated in a subset of 90 (30 HPV positive and 60 HPV negative) CRC samples
by immunohistochemistry.
Results: HPV DNA was found in 14.2% of the CRC samples with HPV16 as the most prevalent type. No significant
differences in clinical and pathological variables were found between HPV positive and negative CRCs, except for
age. HPV positive patients were significantly younger (p = 0.05). There was no significant correlation between the
presence of HPV and overexpression of p16
INK4A (p = 0.325).
Conclusions: In conclusion, the presence of oncogenic HPV DNA in a small cohort of CRC samples may suggest
that HPV may be involved in the carcinogenesis of some CRC. However, contrary to what has been observed in
head and neck squamous cell cancer and cancer of the uterine cervix, p16
INK4A does not seem to be a surrogate
marker for an active HPV infection in CRC. Therefore, further functional analyses are necessary to elucidate the role
of HPV in CRC.
Background
Colorectal cancer (CRC) is one of the most common
malignancies throughout the Western World. Surgery is
the cornerstone in the treatment of patients with CRC
and is followed by adjuvant chemotherapy and radio-
therapy for specific subgroups of patients [1]. Although
many risk factors for development of CRC have been
identified, the molecular mechanisms related to the col-
orectal carcinogenesis remain to be elucidated [2].
Already, for quite some time studies have given evidence
for an association of human papillomavirus (HPV) and
CRC [2-12]. Based on the well-recognized etiologic role
of HPV in cervical, anogenital and oropharyngeal carci-
nogenesis, a potential role of HPV in colorectal carcino-
genesis has been suggested. However, so far the
outcome of studies investigating this provided contradic-
tory results [2-12]. Many authors [2-5,7,8,10-12] were
able to detect HPV DNA in CRC by different laboratory
techniques, but others failed to demonstrate its presence
[9,13-16]. Despite the eventual presence of HPV DNA * Correspondence: vanessa.deschoolmeester@ua.ac.be
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ply a casual passenger or whether it has a causal role in
colorectal carcinogenesis. A p a r tf r o mag e n e r a lc o n t r i -
bution to fully understand the biology of this disease,
such a causal role of HPV in colorectal carcinogenesis
could have important implications in patient care and
colorectal cancer prevention.
The HPV viral oncogenes E6 and E7 have shown to be
the main contributors to the development of HPV
induced cancers. These oncogenes have the ability to
bind host cell regulatory proteins, especially tumor sup-
pressor gene products [17]. The HPV oncoprotein E7 is
known to bind and inactivate hypophosphorylated reti-
noblastoma protein (pRB) [18], which eventually leads
to upregulation of p16
INK4A.P 1 6
INK4A is a tumor sup-
pressor protein that inhibits cyclin dependant kinases
(CDK)-4 or -6 binding to cyclin D which regulates the
G1 cell cycle checkpoints [19,20]. Overexpression of
p16
INK4A is considered to be strong and consistent in
HPV-induced cancers [21]. Therefore, overexpression of
p16
INK4A, as detected by immunohistochemistry, has
shown to be a useful adjunct to cytology in cervical can-
cer screening [22], a reliable marker of human papillo-
mavirus-induced oral high-grade squamous dysplasia
[23], and a useful adjunct in the assessment of biopsies
for HPV-associated anal intraepithelial neoplasia [24].
Furthermore, in primary rectal squamous cell carcinoma
(SCC) there was a clear association between strong reac-
tivity for p16
INK4A and the presence of high-risk HPV
[25]. However, that study was limited to three patients.
The aim of the present study was to investigate the
presence of HPV DNA in a series of colorectal carcino-
mas. In a second part of the study, overexpression of
p16
INK4A was investigated as a marker for the presence
of an active HPV oncoprotein E7 in a subset of the
above mentioned series of colorectal cancers. Subse-
quently, the results were analyzed for correlation with
prognostic clinical features for disease outcome and
pathological variables.
Methods
1. Tissue samples
Material from a previous study of patients with CRC
treated at the Antwerp University Hospital in Edegem
or the St. Augustinus Hospital in Wilrijk [26] was used
for HPV detection as described below. A total of 232
CRC samples were eligible for HPV detection. This
comprised 90 females and 142 males with a median age
of 59.4 years (range 30 to 88 years). TNM staging was
determined and the distribution was as follows: 27
patients were classified as stage I (12.2%), 68 as stage II
(30.6%), 74 as stage III (33.3%) and 53 as stage IV
(23.9%). Seventy patients had a tumor located in the
proximal region of the colon (30.2%), while 80 tumors
were found in the distal colon (34.5%) and 71 in the
rectum (30.6%).
All HPV positive tumors, except three (n = 30), plus
two randomly chosen HPV negative tumors per HPV
positive tumor (n = 60) were used for p16
INK4A immu-
nohistochemistry. Three HPV positive samples could
not be investigated by immunohistochemistry since the
paraffin blocks were no longer available. The study was
approved by the local Ethics Committee of the Univer-
sity of Antwerp and was conducted in accordance with
the ethical principles stated in the most recent version
of the Declaration of Helsinki.
2. DNA isolation
Tumor DNA was obtained from formalin-fixed, paraffin
embedded tissue blocks. After manual microdissection
to enrich for tumor cells, DNA was isolated as described
previously [27]. After DNA extraction, adequate DNA
isolation was confirmed by b-globin PCR [28], generat-
ing a fragment of 110 bp.
3. PCR and genotyping analysis of HPV
Since formalin-fixed paraffin embedded materials often
yield poorly amplifiable DNA, the efficacy of the primer
pair is inversely correlated with the length of the ampli-
mers and the primers should be designed to amplify a
relatively short PCR fragment [29]. DNA samples were
f i r s tt e s t e di nag e n i t a lH P Vb r o a ds p e c t r u mP C Ru s i n g
10 non-biotinylated short PCR fragment (SPF) primers.
T h eS P Fp r i m e r ss e t sa r ed e s i g n e dt oa m p l i f ya6 5b p
fragment located within the L1 region of HPV [30,31]
allowing highly sensitive detection of HPV DNA. PCR
reactions were performed in a final volume of 50 μl con-
taining 1.25 units of iTaq DNA polymerase (BioRad,
Nazareth, Belgium), 2 mM MgCl2, 200 μMd e o x y n u -
cleotide triphosphate, 1× iTaq buffer, 15 pmol of each
of the forward and reverse primers and 10 μl of isolated
DNA. The PCR reactions were carried out using the
iCycler (BioRad) as previously described [32], except
that activation of the enzyme was carried out for 3 min
at 95°C. Each experiment was performed with separate
positive (1 pg and 10 pg HPV16 stable SiHa cells) and
negative PCR controls. After analysis on ethidiumbro-
mide stained agarose gel analysis, positive samples were
re-amplified using biotinylated SPF10 primers (InnoGe-
netics, Ghent, Belgium).
HPV genotyping was performed using reverse hybridi-
z a t i o nb yt h eI N N O - l i n ep r o b ea s s a y( I N N O - L i P A ,
Innogenetics) as described earlier [30]. The current ver-
sion of the SPF10 LiPA contains probes for high-risk
HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59, 66, 68 and 70, and low risk HPV genotypes 6, 11,
34, 40, 42-44, 53, 54 and 74. The hybridization steps
were carried out following the INNO-LiPA kit’s
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poly d(T) tail) were immobilized in parallel lines on
nitrocellulose membrane strips by the supplier; 10 μlo f
the PCR product, containing biotin at the 5’ end of the
primers, was denaturated by adding 10 μlo fN a O H
solution. After hybridization of the PCR product to the
probes on the strip under stringent conditions, followed
by stringent washing, the hybrids were detected by alka-
line phosphatase/streptavidin conjugate and subtrate
(5-bromo-4-chloro-3-indolylphosphate and nitroblue tet-
razolium), resulting in a purple precipitate at the posi-
tive probe lines. After drying, the strips were interpreted
visually by using the INNO-LiPA HPV genotyping v2
interpretation chart [33].
4. Immunohistochemistry
Five μm-thick sections were prepared from formalin-
fixed paraffin-embedded tissue for IHC. Sections were
deparaffinized in toluene, dehydrated and subjected to
heat antigen retrieval in Epitope retrieval solution (as
supplied in the CINtec Histology Kit, mtm laboratories,
Heidelberg, Germany) in a heating bath for 30 min. at
95 (± 1)°C.
Sections were subsequently stained using the CINtec
Histology Kit (mtm laboratories) on a Dako Autostainer
Plus system (DAKO, DakoCytomation, Glostrup, Den-
mark). Endogenous peroxidase activity was quenched by
incubating the slides in peroxidase blocking reagent for
10 minutes. Incubation with mouse anti-human
p16
INK4A monoclonal antibody (diluted 1:100) was per-
formed for 30 minutes at room temperature. Sites of
binding were detected using 3,3’-diaminobenzidine
(DAB
+) as chromogen according to the manufacturers
instructions. The sections were counterstained with hae-
matoxylin, dehydrated, cleared and mounted.
5. MSI analysis
All cases had been previously analyzed for MSI status
[26]. After manual microdissection of formalin-fixed,
paraffin embedded tissue blocks, DNA was isolated as
described previously [27]. MSI analysis was performed
using the mononucleotide multiplex system as described
earlier [34]. In short, the sense primers were chemically
labeled at the 5’ end with FAM™ fluorescent dyes. PCR
was carried out in a final volume of 25 μl containing
200 μmol/L dNTPs (MBI Fermentas, St. Leon-Rot, Ger-
many), 500 nM of each sense and antisense primer
(Eurogentec, Seraing, Belgium), 1 × PCR buffer (60 mM
Tris SO4 (pH 8.9), 18 mM (NH4)SO4 and 2 mM
MgSO4) and 1 unit Discoverase dHPLC DNA polymer-
ase (Invitrogen, Merelbeke, Belgium). Fluorescent PCR
products were analyzed by capillary electrophoresis
using an ABI 3100 Genetic Analyzer (Applied Biosys-
tems, Lennik, Belgium) and Genemapper Software 3.7.
6. Statistics
Prognostic relevance of HPV was assessed by survival
analysis. Survival probability was estimated using the
Kaplan and Meier method. Differences were tested
using the log rank statistic. The median follow up for
OS and DFS was 4.5 and 3.7 years respectively for the
entire study population and 5.8 and 4.8 years respec-
tively for the subpopulation of 90 colorectal tumors
used for p16
INK4A IHC.
Possible associations between the presence of HPV-
DNA and clinicopathological parameters of colorectal
cancers were investigated using the c
2-test or Fisher’s
exact test (when appropriate) for categorical variables
and using Student t-test or Mann-Whitney U test (when
appropriate) for continuous variables. In order to assess
the independent prognostic contribution of HPV, a mul-
tiple Cox regression analysis was conducted. All analyses
were conducted using SPSS (version 16.0). Significance
for all statistics was two-tailed and recorded if p < 0.05.
Results
1. HPV detection and genotyping
All tissue samples were positive for the b-globin gene,
indicating that DNA was available for molecular analy-
sis. HPV DNA was detected in colorectal tissue in
33 out of 232 patients (14.2%) using SPF10 PCR.
HPV DNA-positive samples were subsequently geno-
typed using the SPF10 LiPA by reverse hybridization
(Innogenetics). In about half of the samples a single
HPV infection was identified (54.5%) whereas the other
HPV-DNA positive samples contained multiple HPV
infections (45.5%). A relative broad spectrum of HPV
genotypes was found, HPV 16 (57.6%) being the most
prevalent type, followed by HPV 18 (45.5%) (Figure 1).
The low risk HPV types 6, 11, 42, 43 and 44 were also
found in a limited number of CRC samples, but, with
one exception (for HPV type 43), always in the presence
of a high risk HPV type.
2. Correlations of HPV with clinicopathological variables
and survival
The median age of the overall population is 59 years.
HPV positive patients were younger (median age: 56
years) than HPV negative patients (median age: 60
years) but the difference was of borderline significance
(p = 0.05). Anatomic location of the tumor had no cor-
relation with the presence of HPV infection. HPV preva-
lence was similar in proximal colon, distal colon, and
rectum (p = 0.565). The location of the tumors through-
o u tt h ec o l o ni nc o r r e l a t i o nt ot h ep r e s e n c eo fH P Vi s
shown in Table 1.
Clinical and pathological features were studied
between HPV positive and negative carcinomas. The
results are shown in Table 2, with no significant
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Page 3 of 10difference being observed. In addition, follow-up for
overall survival (OS) and disease free survival (DFS) was
available for 220 and 194 colorectal cancer patients,
respectively. At the end of the observation period, 86 of
the 220 (39.3%) patients had died while 72 of the 194
(37.3%) had experienced a recurrence of the tumor. All
deaths were tumor related. No statistically significant
difference in OS (HR: 0.73, p = 0.35) and DFS (HR:
0.84, p = 0.61) was found between HPV positive and
HPV negative CRC patients in univariate analysis.
3. P16
INK4A expression in CRC
P16
INK4A stained slides (n = 90) were scored on two sepa-
rate aspects: the number of P16
INK4A positive tumor cells
present (0: <5%; 1: 5-25%; 2: 25-50%; 3: > 50%), and the
intensity of p16
INK4A staining (0 = absent; 1 = weak; 2 =
moderate; 3 = strong). Some examples of the different
scores are shown in Figure 2. After the development of
Figure 1 Frequencies of different HPV-types detected in HPV-DNA positive CRC tissue samples.
Table 1 Location of the tumors throughout the colon in
correlation to the presence of HPV.
HPV positivity n % % total
Proximal caecum 6 18.2 39.4
hepatic flexture 3 9.1
colon ascendens 1 3.0
right hemicolon 3 9.1
Distal rectosigmoid 4 12.1 30.3
sigmoid 5 15.2
colon descendens/sigmoid 1 3.0
Rectum 10 30.3 30.3
N = number of HPV positive samples, % = percentage of HPV positive
samples per location separately, total %: percentage of HPV positive samples
in proximal, distal and rectal tumors.
Table 2 Possible associations between HPV and
clinicopathological parameters of colon cancer
- HPV
%
+%
MSI MSS 187 94.4 31 93.9 1
MSI 11 5.6 2 6.1
age (median) 56 60 0.05
gender male 119 59.8 23 69.7 0.337
female 80 40.2 10 30.3
grade of differentiation good 83 44.1 12 40.0 0.764
average 87 46.8 16 53.3
poor 17 9.0 2 6.7
location proximal 57 30.3 13 39.4 0.565
distal 70 37.2 10 30.3
rectum 61 32.4 10 30.3
lymph nodes + 97 86.6 82 89.1 0.670
- 15 13.4 10 10.9
stage I 25 13.0 3 9.7 0.265
II 55 28.7 13 41.9
III 62 32.3 12 38.7
IV 50 26.0 3 9.7
adjuvant yes 62 37.8 22 73.3 0.303
no 102 62.2 8 26.7
Possible associations were investigated using the c
2-test or Fisher’s exact test
(when appropriate) for categorical variables and using Student t-test or Mann-
Whitney U test (when appropriate) for continuous variables (MSI:
microsatellite instability, MSS: microsatellite stability).
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month interval, to assess the reproducibility of the scoring
system. Although some differences were noted, both in
cell numbers and in intensity, the reproducibility of the
scoring system was high (Kappa: 0.831 and 0.742 for cell
numbers and intensity respectively). Both aspects were
subsequently weighed to come to a final score as shown in
Table 3, again, reproducibility after a two month interval
was very high (Kappa: 0.975). Seventy-four percent (n =
67) of all CRC tumors showed p16 expression ranging
from weak (n = 11) over moderate (n = 18) to strong (n =
38). The results of p16
INK4A IHC in relation to presence
or absence of HPV are given in Table 4. It is obvious from
these results that there is no significant correlation
between the presence of HPV and overexpression of
p16
INK4A (p = 0.325) in the colorectal cancer tissues
examined.
4. Correlation of p16
INK4A expression with
clinicopathological variables and survival
Anatomic location of the tumor showed a significant
correlation with the overexpression of p16
INK4A. Tissues
obtained from the proximal colon showed significantly
less expression of p16
INK4A compared to tissues taken
from the distal colon and the rectum (p = 0.002). The
location of the tumors throughout the colon in correla-
tion to the p16
INK4A expression is shown in Table 5.
There was also a trend towards a correlation between
p16
INK4A expression level and stage (p = 0.066). Clinical
and pathological features were studied between carcino-
mas with and without expression of p16
INK4A.T h e
results are shown in Table 4, with no significant differ-
ences being observed.
Figure 2 Immunohistochemical analysis of p16
INK4A expression in colorectal carcinomas.A :n op 1 6
INK4A expression (negative) in tumor
cells. B: weak expression of p16 in tumor cells. C: moderate expression of p16
INK4A in tumor cells and D: strong expression of p16
INK4A with a
strong intensity in tumor cells.
Table 3 Scoring system for P16
INK4A
Intensity
# cells 0 1 2 3
0 negative negative negative negative
1 weak weak moderate
2 weak moderate strong
3 strong strong
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d i s e a s ef r e es u r v i v a l( D F S )w a sa v a i l a b l ef o r8 8a n d8 6
colon cancer patients, respectively. At the end of the
observation period, 37 (42%) patients had died while 31
(36%) had experienced a recurrence of the tumor. All
deaths were tumor related. No statistically significant
difference in OS (HR: 1.06, p = 0.70) and DFS (HR:
0.96, p = 0.76) was found between CRC patients with
and without p16
INK4A expression.
Discussion
Oncogenic papillomaviruses have shown to be involved
in benign and malignant lesions of the cervix and other
anogenital sites [10]. Although the squamous cell
epithelium is the most frequent target site of human
papillomavirus (HPV) infection, similar infections have
been demonstrated in other neoplasms, including ade-
nocarcinomas of the cervix [3].
Based on its well-known role in cervical and anogen-
ital carcinogenesis, some studies proposed an association
between HPV and CRC [2-12]. DNA viruses are known
to activate proto-oncogenes (p53, pRB and c-myc...) [3]
and a collaboration of the ras oncogene with HPV E6/
E7 genes inducing full transformation of normal cells
has been suggested by several groups [12,35-38].
The presence of HPV DNA in colonic neoplasms is a
conflicting issue. Although earlier studies have failed to
detect HPV DNA in colon biopsy samples [13,14], more
recent reports have suggested that infection with HPV16
and 18 may be etiologically associated with some cases of
CRC [2-5,7,8,10-12,39-41]. In the present study, HPV
DNA was found in 14.2% of CRC. Single infections as well
as multiple infections were present and all positive sam-
ples, except one, contained at least one high-risk HPV
type. The HPV frequency is lower than that found in pre-
vious studies where HPV was detected in 21.9 - 97% of
Table 4 Possible associations between p16
INK4A expression and clinicopathological parameters of colon cancer
p16 expression
neg % weak % mod % strong % P
HPV - 14 60.9 10 90.9 12 66.7 24 63.2 0.325
+ 9 39.1 1 9.1 6 33.3 14 36.8
MSI MSS 19 86.4 11 100.0 17 94.4 37 97.4 0.266
MSI 3 22.6 0 0.0 1 5.6 1 2.6
age (median) 63 70 66 65 0.344
gender male 10 43.5 7 63.6 12 66.7 21 55.3 0.466
female 13 56.5 4 36.4 6 33.3 17 44.7
lymph nodes - 9 60.0 6 66.7 6 66.7 24 68.6 0.951
+ 6 40.0 3 33.3 12 33.3 11 31.4
grade of differentiation good 12 54.5 7 63.6 8 44.4 18 51.4 0.875
moderate 7 31.8 3 27.3 9 50.0 13 37.1
poor 3 13.6 1 9.1 1 6.6 4 11.4
location proximal 16 69.6 2 18.2 4 22.2 8 22.2 0.002
distal 2 8.7 3 27.3 9 50.0 16 44.4
rectum 5 21.7 6 54.5 5 27.8 12 33.3
stage I 3 13.0 4 40.0 2 11.8 4 10.8 0.066
II 8 34.8 2 20.0 4 23.5 18 48.6
III 10 43.5 4 40.0 6 35.3 13 35.1
IV 2 8.7 0 0.0 5 29.4 2 5.4
adjuvant therapy no 6 30.0 6 75.0 5 33.3 15 55.6 0.186
yes 14 70.0 2 25.0 10 66.7 12 44.4
Possible associations were investigated using the c
2-test or Fisher’s exact test (when appropriate) for categorical variables and using Student t-test or Mann-
Whitney U test (when appropriate) for continuous variables (MSI: microsatellite instability, MSS: microsatellite stability).
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might be attributed to methodological differences (for
instance the use of L1 versus E6/7 primers sets) among
the studies, or differences in sensitivity of the methods
used for the analysis (for instance due to differences in
amplicon length, since it has been shown that the effi-
ciency of the primer pair is inversely correlated to the
length of the amplicon in formalin fixed paraffin
embedded tissues [29]). In addition, regional variations in
the prevalence of HPV infection, which is known to be
influenced by the ethnical and geographical origin of the
individuals being tested, might also contribute to the dif-
ferences observed among published studies [2,7]. However,
we took the necessary precautions (during microdissec-
tions, DNA extractions and PCR reagents preparations) to
avoid cross-contamination and the SPF10 PCR is proven to
be a very sensitive HPV detection technique [30,31].
Modes of transmission of HPV infection in the colon
region have not been fully resolved; however, anal trans-
mission and an association between sexual behavior and
risk for HPV-positive cancers have been suggested [10]. In
accordance to Bodaghi et al. [11] and Damin et al [2],
there was no significant difference in the distribution of
the virus throughout the colon (p = 0.565). Rates of viral
detection were similar in tissues taken from the proximal
colon, the distal colon or the rectum, suggesting that HPV
is not a result of retrograde viral transmission from the
anogenital area [2]. One possible hypothesis could be that
during a screening colonoscopy, an anal HPV infection
might be transported from the anal region throughout the
colon [42]. Likewise, it has been shown that HPV DNA
can be present on specula, used for taking PAP smears,
and autoclave sterilization is the method of choice to era-
dicate these viruses [41,43]. Transfer by colonoscopy
might also explain the lower rate of HPV infection in our
study population because screening for CRC is much less
common in Belgium than in the US. However, considering
that HPV infection is mainly transmitted by cell surface
contact, the route of viral transmission to the colon
remains to be determined [2].
As seen in most other studies, high-risk HPV type 16
was the most prevalent type in colorectal tissues in this
study, followed by high-risk HPV type 18. These types
have been reported to suppress tumor suppressor pro-
teins functions and play an important part in carcino-
genesis [7]. Low risk types were also detected in CRC
but, with one exception, always along with the presence
of a high risk type. However, in order to suggest that
HPV might be involved in colon cancer carcinogenesis,
viral DNA incorporation into the host genome needs to
be demonstrated by in situ hybridization. In addition,
the presence or absence of HPV in a non-malignant
control group and tumor adjacent tissue needs to be
investigated in order to determine whether HPV is
merely an epiphenomenon in CRC or rather a potential
cofactor in the development of the disease [2].
No significant differences in clinical and pathological
variables were found between HPV positive and nega-
tive colorectal carcinomas. HPV positive patients
showed a trend to be younger than HPV negative
patients. A similar observation has been made in HPV
positive oral squamous cell cancer, a disease in which
HPV appears to play an etiologic role [44-46]. Other
reports in CRC have failed to demonstrate a correlation
between the presence of HPV and prognostic factors
[2,3,5,7,8,10-12]
In the second part of the study, overexpression of
p16
INK4A was investigated as a marker for the presence
Table 5 The location of the tumors throughout the colon in correlation to the p16
INK4A expression
p16 expression
negative weak moderate strong
proximal right hemicolon 7 30.4% 2 18.2% 2 11.1% 2 5.6%
caecum 3 13.0% 0 0.0% 1 5.6% 3 8.3%
colon asecendens 1 4.3% 0 0.0% 0 0.0% 1 2.8%
colon transversum 1 4.3% 0 0.0% 0 0.0% 1 2.8%
hepatic angle 4 17.4% 0 0.0% 0 0.0% 1 2.8%
jejenum 0 0.0% 0 0.0% 1 5.6% 0 0.0%
distal left hemicolon 0 0.0% 0 0.0% 1 5.6% 3 8.3%
recto-sigmoid 1 4.3% 0 0.0% 2 11.1% 1 2.8%
sigmoid 1 4.3% 3 27.3% 6 33.3% 12 33.3%
rectal rectum 5 21.7% 6 54.5% 5 27.8% 12 33.3%
TOTAL 23 100.0% 11 100.0% 18 100.0% 36 100.0%
The actual location of the tumor in the large bowel could not be retrieved in 2 cases.
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colorectal carcinomas. It has been demonstrated that
p16
INK4A overexpression might specifically identify HPV
infections that are biologically relevant in the carcino-
genesis of head and neck squamous cell carcinomas and
cervical carcinomas. However, it should be noted that
expression of p16
INK4A is not limited to HPV-positive
tumors, and the use of this marker alone as an indicator
of biologically relevant HPV infections inevitably entails
the risk of including some HPV negative p16
INK4A posi-
tive results [45]. In the present study, no significant cor-
relation could be found between p16
INK4A expression
and the presence of an HPV infection. This might be
explained by the fact that p16
INK4A is aberrantly methy-
lated in about 40% of sporadic CRC and is significantly
correlated with loss of tumor suppressor function [47].
In the current study 26% of analyzed samples did not
show p16
INK4A expression, which is in agreement with
the literature. Few studies have investigated the relation-
ship between p16
INK4A expression and colorectal adeno-
carcinoma. The reported frequency of p16
INK4A protein
expression in CRC varies from 17 to 99%, with the
majority of investigations showing p16
INK4A expression
in more than two third of CRC [48]. In this study, we
noted that p16
INK4A protein was expressed in 74% of
the colorectal adenocarcinomas and more than half (n =
38) showed a high level of p16
INK4A expression. P16 is a
nucleoprotein; the presence of staining in both the
nuclei and the cytoplasm supports the finding that p16
gene is overexpressed. The change in subcellular loca-
tion of the overexpressed nucleoprotein might account
for its role in CRC carcinogenesis. The mechanism
inducing the p16
INK4A overexpression is probably differ-
ent from promoter methylation and could presumably
result from a compensatory response to cell cycle dereg-
ulation [48]. CDK4 overexpression could be the initial
event leading to a reactive overexpression of p16
INK4A
and to a break in the G1-S transition through pRb phos-
phorylation [49].
No significant differences in clinical and pathological
variables were found between CRC samples expressing
p16
INK4A and those not expressing p16
INK4A, except for
location. In accordance with others [47,48] p16
INK4A
p r o t e i ne x p r e s s i o nw a sm o r eo f t e ns e e ni nt h ed i s t a l
colon and the rectum. In addition, there was a trend
towards an association between strong p16
INK4A expres-
sion and stage II and III tumors.
T h ep r o g n o s t i cr o l eo fp 1 6
INK4A protein has been
investigated in five studies. Three studies noted that
p16
INK4A expression was associated with poorer survival
[48-50]. In accordance to Norrie et al. [51] and Tada et
al. [52], we found no relationship between p16
INK4A
expression and patient survival.
Conclusions
In conclusion, the presence of oncogenic HPV DNA in a
small cohort of CRC samples, with high risk HPV 16 as
the most prevalent type, was confirmed in the present
study. However, in order to suggest that HPV might be
involved in colon cancer, viral DNA incorporation into
the host genome needs to be demonstrated by in situ
hybridization. Additionally, the presence or absence of
HPV in a non-malignant control group and tumor adja-
cent tissue needs to be investigated in order to determine
whether HPV is merely an epiphenomenon in CRC or
rather a potential cofactor in the development of the
disease.
In addition, contrary to what has been observed in
head and neck squamous cell cancer and cancer of the
uterine cervix, p16
INK4A does not seem to be a surrogate
marker for an active HPV infection in CRC. Therefore,
further functional analyses are necessary to elucidate the
significance of the presence of HPV in CRC.
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